|
WO2015054542A1
|
|
Methods of treating, reducing the incidence of, and/or preventing ischemic events
|
|
WO2015031313A2
|
|
Methods for treating bacteremia and osteomyelitis using oritavancin
|
|
US2016101148A1
|
|
Treatment and prevention of bacterial skin infections using oritavancin
|
|
CN104968199A
|
|
Methods for controlling blood pressure and reducing dyspnea in heart failure
|
|
US2013303477A1
|
|
Maintenance of Platelet Inhibition During Antiplatelet Therapy
|
|
US2013303478A1
|
|
Maintenance of platelet inhibition during antiplatelet therapy
|
|
WO2014209389A1
|
|
Maintenance of platelet inhibition during antiplatelet therapy
|
|
US8680052B1
|
|
Methods of treating, reducing the incidence of, and/or preventing ischemic events
|
|
WO2014142780A1
|
|
Methods of treating, reducing the incidence of, and/or preventing ischemic events
|
|
US2013158079A1
|
|
Clevidipine emulsion formulations containing antimicrobial agents
|
|
WO2013103567A2
|
|
Methods of blocking platelet activation during extracorporeal circulation using cangrelor
|
|
US2014296147A1
|
|
Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010
|
|
CA2844464A1
|
|
Methods for treating properdin-related diseases or disorders
|
|
WO2013016529A2
|
|
Disk diffusion assay for oritavancin
|
|
NZ617195A
|
|
Short-acting dihydropyridines (clevidipine) for use in reducing stroke damage
|
|
WO2012051116A1
|
|
Clevidipine emulsion formulations containing antimicrobial agents
|
|
EP2624820A2
|
|
Antimicrobial preservation of propofol emulsions
|
|
US7985733B1
|
|
Buffer-based method for preparing bivalirudin drug product
|
|
US7803762B1
|
|
Ready-to-use bivalirudin compositions
|
|
NZ591205A
|
|
Pharmaceutical compositions comprising clevidipine and methods for producing low impurity concentrations of the same
|
